Trials / Completed
CompletedNCT07158398
Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate
A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Vimseltinib on BCRP and OATP1B1 Inhibition in Healthy Male Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Deciphera Pharmaceuticals, LLC · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to determine the effect of Vimseltinib dosing on breast cancer resistance protein (BCRP) and organic-anion-transporting polypeptide 1 B1 (OAT1PB1) activity by using rosuvastatin in healthy male participants. This study will also evaluate the safety and tolerability when vimseltinib is co-administered with rosuvastatin in healthy male participants. This study will last approximately 26 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vimseltinib | Administered orally |
| DRUG | Rosuvastatin | Administered orally |
Timeline
- Start date
- 2025-10-31
- Primary completion
- 2025-12-08
- Completion
- 2025-12-08
- First posted
- 2025-09-05
- Last updated
- 2026-01-15
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07158398. Inclusion in this directory is not an endorsement.